bertayfybuqutyp.blogspot.com
The 16-week trial gave 159 cancer patientd at 35 sites inthe U.S. and Argentina eithe r one or three milligram dosesof Ostraine, a selective androge n receptor modulator. The results show the one milligram dose gave patients 0.2 pounds of lean body The three milligram dose increased muscle mass by 2.9 and 3.3 "Approximately half of all cancere patients suffer from the devastating effects of cancef induced muscle loss,” Adrian an investigator in the clinical trial and professor of medicine and oncology at , said in a “Increasing lean body mass may improve quality of life and even their responser to cancer treatment.
” GTx (Nasdaq: GTXI) and MRK) are collaborating to develop Ostrainew as part of a broader programk for SARMs, a new classw of drugs with the potential to treaf musculoskeletal conditions. Shares of Memphis-based GTx, a specialty pharmaceutical company, closed 32 centsw higher Thursdayto $9.30 per share, up 3.44 percenf for the day.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment